Last reviewed · How we verify
BMS-986504
BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells.
BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | BMS-986504 |
|---|---|
| Also known as | MRTX1719 |
| Sponsor | Bristol-Myers Squibb |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking the PD-1 receptor, BMS-986504 allows T cells to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-1 inhibitors, such as nivolumab and pembrolizumab, which have shown efficacy in various types of cancer. However, the specific effects of BMS-986504 may vary depending on the type of cancer and individual patient characteristics.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (PHASE2, PHASE3)
- A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) (PHASE2)
- A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (PHASE2)
- A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (PHASE2, PHASE3)
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (PHASE1)
- A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors (PHASE1)
- Clinical Trial of BMS-986504 in Recurrent GBM Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986504 CI brief — competitive landscape report
- BMS-986504 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI